Antibody-drug conjugate is a new type of targeted therapeutic drug, mainly used for the treatment of cancers. The basic design philosophy originated from the notions of “magic bullet” and “drug targeting”, i.e. delivering drugs to the target region via specific carriers, which was firstly proposed by Paul Ehrlich in 1931. An ADC drug is composed of three independent parts: an antibody or antibody-like ligand, small molecular drugs, and linkers that conjugate the drugs to the ligand. As novel targeted therapeutic agents, ADC has experienced fast development in recent years.
NewBio Therapeutics has established a highly efficient ADC technology platform so far. The platform covers all stages of ADC development, including target selection, monoclonal antibody development, linker and cytotoxic drug design/synthesis, ADC candidate screening, ADC conjugation process development, IND enabling study and clinical trial design, etc. Based on this platform, we have successfully developed a strong pipeline with a series of different ADC drug candidates. Two ADC program, NBT828 and NBT508, are in phase I clinical trials, while five more are in preclinical/discovery stages.